UNSPSC 51241110: Latanoprost

This classification denotes a prostaglandin analogue and anti-glaucoma agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6Z5B6HVF6O. European Medicines Agency schedules Latanoprost in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08409MIG. Latanoprost generally arises in the molecular formula C26H40O5.

UNSPSC 51241110 Latanoprost, a Commodity code, encompasses ophthalmic pharmaceutical products—specifically prostaglandin analogue eye drops used to treat glaucoma and ocular hypertension—procured by state and local health systems, corrections departments, and cooperative purchasing alliances to supply clinical facilities and inmate populations. State and local governments acquire latanoprost as part of broader pharmaceutical procurement programs through multistate cooperative purchasing vehicles and individual agency formularies, typically bundled with generic and over-the-counter pharmaceutical products in volume contracts negotiated with manufacturers and distributed through authorized pharmaceutical wholesalers.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP (S1070000015802) on January 20, 2026, due March 26, 2026, to establish multiple contracts for generic pharmaceuticals and OTC products available to participating state and local government facilities across Minnesota, Oregon, and other member jurisdictions. The RFP requires vendors to supply products with specific National Drug Codes through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with awarded products effective July 1, 2026. Vendors must maintain contractual relationships with at least two of the three authorized wholesalers, certify compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act, carry insurance including $5 million commercial general liability and $2 million network security and privacy liability, and submit pricing in flat-price or net-price formats with a competitive weighting of 75 percent on price competitiveness and 10 percent on fixed pricing. The contract term is two years for new vendors with optional extensions at MMCAP's discretion, and incumbent vendors' amendments extend through June 30, 2028.